Back to top
more

scPharmaceuticals (SCPH)

(Delayed Data from NSDQ)

$4.44 USD

4.44
434,538

+0.42 (10.45%)

Updated Jun 5, 2024 04:00 PM ET

After-Market: $4.44 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SCPH

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

scPharmaceuticals, Inc. [SCPH]

Reports for Purchase

Showing records 21 - 38 ( 38 total )

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

08/12/2021

Company Report

Pages: 5

Planned 4Q Resubmission Remains on Track as Furoscix Takes Center Stage at HFSA; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

07/15/2021

Daily Note

Pages: 5

Key Takeaways from FREEDOM-HF Topline Conference Call: Furoscix Benefits All Stakeholders; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

07/14/2021

Daily Note

Pages: 4

FREEDOM-HF Quantifies Significant Cost Savings with Furoscix and Conference Call Scheduled for 8:30 am; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

07/02/2021

Daily Note

Pages: 3

ScPharma and FDA Align on Furoscix Resubmission With No Additional Device Modifications Needed; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

05/13/2021

Company Report

Pages: 5

Plugging Away at Pre-Resubmission Testing; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

03/24/2021

Company Report

Pages: 5

Preparing for Furoscix Resubmission in 3Q; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

02/24/2021

Daily Note

Pages: 4

Path Forward on Furoscix Resubmission Comes Into Focus; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

12/07/2020

Daily Note

Pages: 4

Furoscix Receives Another CRL, Though No Clinical Deficiencies Identified; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

11/17/2020

Company Report

Pages: 5

With Furoscix PDUFA Nearing, scPharma Prepares for Launch; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

10/16/2020

Daily Note

Pages: 4

HCW @ Home With ScPharma: The Furoscix Value Proposition; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

09/30/2020

Daily Note

Pages: 4

Top Five Takeaways From KOL Call on Furoscix; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

08/14/2020

Company Report

Pages: 5

ScPharma Reports Second Quarter Earnings and Prepares for December PDUFA Date; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

07/02/2020

Daily Note

Pages: 3

Taking the Final Step With NDA Resubmission; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

05/13/2020

Company Report

Pages: 5

One Step Closer to Furoscix NDA Resubmission in Mid-2020; Reiterate Buy, Raising PT to $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

03/25/2020

Company Report

Pages: 5

Poised for Resubmission of Furoscix NDA; Reiterate Buy With PT of $13

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

12/16/2019

Daily Note

Pages: 3

A Big Step Forward for Furoscix

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

11/14/2019

Company Report

Pages: 4

Checking off the Factors for Resubmission; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

10/15/2019

Company Report

Pages: 22

Making the Old New Again; Initiate With Buy and $13 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 75.00

Research Provided by a Third Party